Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): Overall survival (OS) results of MM-003 after adjustment for crossover.
Gareth J Morgan
Honoraria - Celgene
Research Funding - Celgene
Jesus San Miguel
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen; Millennium; MSD; Novartis; Onyx
Sujith Dhanasiri
Employment or Leadership Position - Celgene
Dawn Lee
Consultant or Advisory Role - Celgene
Antonio Palumbo
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Millennium; Onyx
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Millennium; Onyx
Thierry Facon
Consultant or Advisory Role - Celgene
Mohamed H. Zaki
Employment or Leadership Position - Celgene
Xin Yu
Employment or Leadership Position - Celgene
Lars Axel Sternas
Employment or Leadership Position - Celgene
Christian Jacques
Employment or Leadership Position - Celgene
Katja C. Weisel
Consultant or Advisory Role - Celgene; Janssen; Onyx
Honoraria - Celgene; Janssen; Onyx
Fritz Offner
No relevant relationships to disclose
Meletios A. Dimopoulos
Honoraria - Celgene; Northwest Biotherapeutics